An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

Overview

This is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive clinical benefit.

Study Type

  • Study Type: Expanded Access

Interventions

  • Drug: Continued Access Arm
    • All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.

Participating in This Clinical Trial

Inclusion Criteria

  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study. – Subject has participated in a clinical trial that evaluated maraviroc and is continuing to derive clinical benefit from maraviroc treatment. – Subject must agree to use an acceptable method of contraception for the duration of the study as outlined at the end of the inclusion criteria. – Subject agrees to the specified study procedures. Exclusion Criteria:

  • Subject who is an investigational site staff member or an employee of the Sponsor that is directly involved in the conduct of the trial. – Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. – Contra-indications to use of maraviroc as described in the Investigator Brochure. – Past documented dual/mixed or C-X-C chemokine receptor type 4 HIV tropism.

Gender Eligibility: All

Minimum Age: 16 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • ViiV Healthcare
  • Collaborator
    • GlaxoSmithKline
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • GSK Clinical Trials, Study Director, ViiV Healthcare

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.